Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2019 4
2020 9
2021 16
2022 13
2023 9
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Results by year

Filters applied: . Clear all
Page 1
Lymphoma: Diagnosis and Treatment.
Lewis WD, Lilly S, Jones KL. Lewis WD, et al. Am Fam Physician. 2020 Jan 1;101(1):34-41. Am Fam Physician. 2020. PMID: 31894937 Free article. Review.
Non-Hodgkin lymphoma is treated with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) with or without rituximab (R-CHOP), bendamustine, and lenalidomide. Hodgkin lymphoma is treated with combined chemotherapy with ABVD (doxorubicin, bleomycin, vinblastine, …
Non-Hodgkin lymphoma is treated with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) with or without rituximab (R-CHOP), …
Hairy Cell Leukemia: Where Are We in 2023?
Mendez-Hernandez A, Moturi K, Hanson V, Andritsos LA. Mendez-Hernandez A, et al. Curr Oncol Rep. 2023 Aug;25(8):833-840. doi: 10.1007/s11912-023-01419-z. Epub 2023 Apr 25. Curr Oncol Rep. 2023. PMID: 37097545 Free PMC article. Review.
How I treat cold agglutinin disease.
Berentsen S. Berentsen S. Blood. 2021 Mar 11;137(10):1295-1303. doi: 10.1182/blood.2019003809. Blood. 2021. PMID: 33512410 Free article. Review.
The author recommends that B cell-directed approaches remain the first choice in most patients requiring treatment. The 4-cycle bendamustine plus rituximab combination is highly efficacious and sufficiently safe and induces durable responses in most patients, but the time …
The author recommends that B cell-directed approaches remain the first choice in most patients requiring treatment. The 4-cycle bendamust …
Current approach to Waldenström Macroglobulinemia.
Ravi G, Kapoor P. Ravi G, et al. Cancer Treat Res Commun. 2022;31:100527. doi: 10.1016/j.ctarc.2022.100527. Epub 2022 Feb 2. Cancer Treat Res Commun. 2022. PMID: 35149375 Free article. Review.
Head-to head comparative data to inform optimal approach are lacking, and a particularly vexing issue for the clinicians is choosing between fixed-duration bendamustine-rituximab (BR) therapy and an indefinite BTK inhibitor-based regimen, given that both approaches are wel …
Head-to head comparative data to inform optimal approach are lacking, and a particularly vexing issue for the clinicians is choosing between …
Waldenström macroglobulinemia: 2021 update on diagnosis, risk stratification, and management.
Gertz MA. Gertz MA. Am J Hematol. 2021 Feb 1;96(2):258-269. doi: 10.1002/ajh.26082. Am J Hematol. 2021. PMID: 33368476 Free article. Review.
Rituximab-monotherapy is inferior to regimens that combine it with bendamustine, an alkylating agent, a proteosome inhibitor, or ibrutinib. Purine nucleoside analogues are active but usage is declining in favor of less toxic alternatives. The preferred Mayo Clinic inductio …
Rituximab-monotherapy is inferior to regimens that combine it with bendamustine, an alkylating agent, a proteosome inhibitor, or ibru …
Hairy cell leukemia: present and future directions.
Kreitman RJ. Kreitman RJ. Leuk Lymphoma. 2019 Dec;60(12):2869-2879. doi: 10.1080/10428194.2019.1608536. Epub 2019 May 9. Leuk Lymphoma. 2019. PMID: 31068044 Free PMC article. Review.
Diffuse large B-cell lymphoma: new targets and novel therapies.
Cheson BD, Nowakowski G, Salles G. Cheson BD, et al. Blood Cancer J. 2021 Apr 5;11(4):68. doi: 10.1038/s41408-021-00456-w. Blood Cancer J. 2021. PMID: 33820908 Free PMC article. Review.
Newer, more effective and non-cytotoxic therapies are an unmet need for patients with diffuse large B-cell lymphoma (DLBCL) and other B-cell malignancies. Recently approved agents include polatuzumab with bendamustine and rituximab, selinexor, and tafasitamab plus lenalido …
Newer, more effective and non-cytotoxic therapies are an unmet need for patients with diffuse large B-cell lymphoma (DLBCL) and other B-cell …
Updates on the Diagnosis and Management of Cold Autoimmune Hemolytic Anemia.
Gertz MA. Gertz MA. Hematol Oncol Clin North Am. 2022 Apr;36(2):341-352. doi: 10.1016/j.hoc.2021.11.001. Epub 2022 Mar 11. Hematol Oncol Clin North Am. 2022. PMID: 35282954 Free PMC article. Review.
Success in the management of cold agglutinin disease with rituximab, fludarabine, bortezomib, and bendamustine has all been reported. Recent studies have demonstrated that the blockade of complement with sutimlimab can stop the hemolysis without the use of systemic chemoth …
Success in the management of cold agglutinin disease with rituximab, fludarabine, bortezomib, and bendamustine has all been reported. …
New Insights in Autoimmune Hemolytic Anemia: From Pathogenesis to Therapy Stage 1.
Barcellini W, Zaninoni A, Giannotta JA, Fattizzo B. Barcellini W, et al. J Clin Med. 2020 Nov 27;9(12):3859. doi: 10.3390/jcm9123859. J Clin Med. 2020. PMID: 33261023 Free PMC article. Review.
Rituximab is advised in first line therapy, followed by rituximab plus bendamustine and bortezomib. Several new drugs are under development including B-cell directed therapies (ibrutinib, venetoclax, parsaclisib) and inhibitors of complement (sutimlimab, pegcetacoplan), sp …
Rituximab is advised in first line therapy, followed by rituximab plus bendamustine and bortezomib. Several new drugs are under devel …
51 results